Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ageas SA/NV stock logo
AGESY
ageas SA/NV
$46.59
-1.5%
$44.44
$37.91
$47.60
$8.76B0.714,482 shs1,645 shs
Arkema S.A. stock logo
ARKAY
Arkema
$101.72
-0.7%
$103.90
$85.58
$114.15
$7.63B1.374,197 shs1,451 shs
Covestro AG stock logo
COVTY
Covestro
$25.64
-0.4%
$26.85
$19.11
$31.76
$9.69B1.2410,957 shs23,903 shs
Renault SA stock logo
RNLSY
Renault
$10.30
-0.8%
$9.46
$6.59
$11.07
N/A1.6636,953 shs23,311 shs
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
$24.38
-1.2%
$24.38
$18.50
$31.96
$6.64B1.811,665 shs200 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ageas SA/NV stock logo
AGESY
ageas SA/NV
-1.48%+1.55%+2.53%+8.20%+6.43%
Arkema S.A. stock logo
ARKAY
Arkema
-0.70%-1.77%-1.81%-8.88%+5.35%
Covestro AG stock logo
COVTY
Covestro
-0.40%-3.37%-5.12%-3.84%+26.38%
Renault SA stock logo
RNLSY
Renault
-0.77%+0.10%+2.79%+38.82%+44.26%
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ageas SA/NV stock logo
AGESY
ageas SA/NV
N/AN/AN/AN/AN/AN/AN/AN/A
Arkema S.A. stock logo
ARKAY
Arkema
N/AN/AN/AN/AN/AN/AN/AN/A
Covestro AG stock logo
COVTY
Covestro
N/AN/AN/AN/AN/AN/AN/AN/A
Renault SA stock logo
RNLSY
Renault
N/AN/AN/AN/AN/AN/AN/AN/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ageas SA/NV stock logo
AGESY
ageas SA/NV
2.20
HoldN/AN/A
Arkema S.A. stock logo
ARKAY
Arkema
3.00
BuyN/AN/A
Covestro AG stock logo
COVTY
Covestro
3.00
BuyN/AN/A
Renault SA stock logo
RNLSY
Renault
2.25
HoldN/AN/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ageas SA/NV stock logo
AGESY
ageas SA/NV
$10.94B0.80$10.33 per share4.51$47.94 per share0.97
Arkema S.A. stock logo
ARKAY
Arkema
$10.30B0.74$26.15 per share3.89$103.04 per share0.99
Covestro AG stock logo
COVTY
Covestro
$18.93B0.51$7.43 per share3.45N/A
Renault SA stock logo
RNLSY
Renault
$56.68BN/A$3.90 per share2.64$21.05 per shareN/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
$763.19M8.71$0.70 per share34.66$2.88 per share8.47

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ageas SA/NV stock logo
AGESY
ageas SA/NV
$1.07BN/A0.006.130.34N/AN/AN/AN/A
Arkema S.A. stock logo
ARKAY
Arkema
$452.36M$5.8017.549.600.454.40%8.92%4.76%N/A
Covestro AG stock logo
COVTY
Covestro
-$286.58M-$2.46N/A71.21N/A-5.81%-8.62%-4.20%N/A
Renault SA stock logo
RNLSY
Renault
$2.38BN/A0.003.34N/AN/AN/AN/AN/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
$134.73M$0.5048.7616.931.3025.75%29.63%18.74%N/A

Latest ARKAY, COVTY, AGESY, SWTUY, and RNLSY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/29/202412/31/2023
Arkema S.A. stock logo
ARKAY
Arkema
$1.87$1.54-$0.33$2.79$2.44 billion$2.39 billion

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ageas SA/NV stock logo
AGESY
ageas SA/NV
$2.234.79%N/AN/AN/A
Arkema S.A. stock logo
ARKAY
Arkema
$3.103.05%N/A53.45%N/A
Covestro AG stock logo
COVTY
Covestro
N/AN/AN/AN/AN/A
Renault SA stock logo
RNLSY
Renault
$0.040.39%N/AN/AN/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ageas SA/NV stock logo
AGESY
ageas SA/NV
N/AN/AN/A
Arkema S.A. stock logo
ARKAY
Arkema
0.40
2.25
1.64
Covestro AG stock logo
COVTY
Covestro
0.39
1.81
1.08
Renault SA stock logo
RNLSY
Renault
N/A
1.11
1.04
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
ageas SA/NV stock logo
AGESY
ageas SA/NV
N/A
Arkema S.A. stock logo
ARKAY
Arkema
N/A
Covestro AG stock logo
COVTY
Covestro
N/A
Renault SA stock logo
RNLSY
Renault
N/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/A

Insider Ownership

CompanyInsider Ownership
ageas SA/NV stock logo
AGESY
ageas SA/NV
N/A
Arkema S.A. stock logo
ARKAY
Arkema
N/A
Covestro AG stock logo
COVTY
Covestro
N/A
Renault SA stock logo
RNLSY
Renault
N/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
ageas SA/NV stock logo
AGESY
ageas SA/NV
44,230187.97 millionN/ANot Optionable
Arkema S.A. stock logo
ARKAY
Arkema
21,10075.04 millionN/ANot Optionable
Covestro AG stock logo
COVTY
Covestro
17,985378.00 millionN/ANot Optionable
Renault SA stock logo
RNLSY
Renault
106,000N/AN/ANot Optionable
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
902272.51 millionN/ANot Optionable

ARKAY, COVTY, AGESY, SWTUY, and RNLSY Headlines

SourceHeadline
Swedish customs seize around 1.4 tons of cocaine in one of the country’s largest-ever drug bustsSwedish customs seize around 1.4 tons of cocaine in one of the country’s largest-ever drug busts
sandiegouniontribune.com - April 23 at 8:56 AM
New CAR T Cell Clinical Trial for Acute Myeloid Leukemia Is First of Its KindNew CAR T Cell Clinical Trial for Acute Myeloid Leukemia Is First of Its Kind
mskcc.org - April 23 at 1:32 AM
What are orphan crops? And why is there a new campaign to get them adopted?What are 'orphan crops'? And why is there a new campaign to get them adopted?
publicradiotulsa.org - April 18 at 3:07 PM
More premature babies born following Swedish parental leave policyMore premature babies born following Swedish parental leave policy
msn.com - April 8 at 5:49 PM
Swedish Scientists Confirm: Knitting Is Your Brains Best FriendSwedish Scientists Confirm: Knitting Is Your Brain's Best Friend
msn.com - April 3 at 5:17 PM
Spring snow storm batters Swedish drivers and governmentSpring snow storm batters Swedish drivers and government
phys.org - April 3 at 5:17 PM
Bulgarian cruise ship crashes into wall on Danube in Austria, injuring 11Bulgarian cruise ship crashes into wall on Danube in Austria, injuring 11
msn.com - March 30 at 3:51 PM
Swedish Maidens’ Choir Sings in J.R.R. Tolkien’s Elvish Language to the Delight of LotR FansSwedish Maidens’ Choir Sings in J.R.R. Tolkien’s Elvish Language to the Delight of LotR Fans
goodnewsnetwork.org - March 29 at 6:54 PM
Investor AB Achieves Strong Performance and Sustainability Milestones in 2023Investor AB Achieves Strong Performance and Sustainability Milestones in 2023
news.europawire.eu - March 27 at 1:27 PM
New oral ITP medicine could be an option for childrenNew oral ITP medicine could be an option for children
thepharmaletter.com - March 26 at 1:27 AM
The unexplained: Giant Swedish archive logs paranormal phenomenaThe unexplained: Giant Swedish archive logs paranormal phenomena
phys.org - March 24 at 7:13 PM
Crown Princess Victoria of Sweden, Swedish Minister Johan Forssell to visit Bangladesh March 18-21Crown Princess Victoria of Sweden, Swedish Minister Johan Forssell to visit Bangladesh March 18-21
msn.com - March 17 at 1:32 PM
Sweden officially joins NATO, becoming alliance’s 32nd memberSweden officially joins NATO, becoming alliance’s 32nd member
komu.com - March 7 at 1:55 PM
Sweden set to become NATOs 32nd member as PM visits WashingtonSweden set to become NATO's 32nd member as PM visits Washington
msn.com - March 7 at 8:55 AM
The opportunities and challenges facing rare disease therapies developersThe opportunities and challenges facing rare disease therapies developers
pharmaphorum.com - February 24 at 8:22 AM
Anticipation rises for RSV rollout as positive data emergesAnticipation rises for RSV rollout as positive data emerges
pharmaceutical-technology.com - February 23 at 10:21 AM
Cytokine release syndrome: how pharma is tackling a 21st century diseaseCytokine release syndrome: how pharma is tackling a 21st century disease
labiotech.eu - February 22 at 7:14 PM
Death and grief in Swedish childrens booksDeath and grief in Swedish children's books
msn.com - February 21 at 5:19 PM
UPDATE 2-Swedens Vattenfall to move ahead with nuclear plansUPDATE 2-Sweden's Vattenfall to move ahead with nuclear plans
msn.com - February 19 at 3:40 PM
Orexo, Sobi agree to advance feasibility study with AmorphOXOrexo, Sobi agree to advance feasibility study with AmorphOX
pharmabiz.com - February 13 at 5:22 AM
Orexo and Sobi agree to advance feasibility study with AmorphOXOrexo and Sobi agree to advance feasibility study with AmorphOX
finanznachrichten.de - February 12 at 9:00 AM
Revolutionizing Historical Research: Swedish Lion AI UnveiledRevolutionizing Historical Research: Swedish Lion AI Unveiled
msn.com - February 10 at 3:07 PM
Heres what Wall Street expects from Swedish Orphan Biovitrum ABs earnings reportHere's what Wall Street expects from Swedish Orphan Biovitrum AB's earnings report
markets.businessinsider.com - February 8 at 2:55 AM
Clues from the ice age can help restore Swedish streamsClues from the ice age can help restore Swedish streams
msn.com - February 6 at 2:10 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

ageas SA/NV logo

ageas SA/NV

OTCMKTS:AGESY
ageas SA/NV, together with its subsidiaries, engages in insurance business in Europe and Asia. The company operates in five segments: Belgium, Europe, Asia, Reinsurance, and General Account. It primarily offers property, casualty, and life insurance products, as well as pension products; and reinsurance products. Its life insurance products include risks related to the life and death of individuals; and non-life insurance products comprise accident and health, motor, fire, and other insurance products, as well as other damages to property covering the risk of property losses or claims liabilities. The company serves private individuals, as well as small, medium-sized, and large companies through independent brokers and the bank channels. ageas SA/NV was founded in 1824 and is headquartered in Brussels, Belgium.
Arkema logo

Arkema

OTCMKTS:ARKAY
Arkema S.A. manufactures and sells specialty chemicals and advanced materials worldwide. The company operates in three segments: Adhesive Solutions, Advanced Materials and Coating Solutions, and Intermediates. The Adhesive Solutions segment provides solutions for construction, renovation of buildings, DIY, durable goods, and packaging and non-woven applications; and supplies technologies used in building activities for businesses and individuals, including sealants, tiles, flooring adhesives and waterproofing systems, and technologies used in industry, which include automotive, textiles, glazing, flexible and rigid packaging, and hygiene markets. This segment also offers performance polymers, such as specialty polyamides, PVDF, polyimides, fluorospecialties, and polyetherketoneketone; and performance additives which includes molecular sieves, organic peroxides, thiochemicals, and hydrogen peroxide. The Advance Materials and Coating Solutions segment offers coating solutions, including comprising EU/US acrylics and coating resins; coating additives, such as sartomer photocure resins and coatex rheology additives. This segment also provides decorative paints, industrial coatings, and adhesives; and solutions for applications in the paper, superabsorbent, water treatment and oil and gas extraction, and 3D printing and electronics industries. The Intermediates segment provides fluorogases and acrylics; and industrial intermediate chemicals used in construction, refrigeration and air conditioning, automotive, coatings, and water treatment sectors. Arkema S.A. was incorporated in 2003 and is headquartered in Colombes, France.
Covestro logo

Covestro

OTCMKTS:COVTY
Covestro AG supplies high-tech polymer materials and application solutions. It operates in two segments, Performance Materials, and Solutions & Specialties. The Performance Materials segment develops, produces, and supplies high-performance materials, such as polyurethanes and polycarbonates, and base chemicals, which include diphenylmethane diisocyanate (MDI), toluylene diisocyanate, long-chain polyols, and polycarbonate resins for use in furniture and wood processing, construction, automotive, and transportation industries, as well as roof structures, insulation for buildings and refrigerators, mattresses, car seats, and other applications. The Solutions & Specialties segment comprises a range of polymer products, including polycarbonates, precursors for coatings and adhesives, MDI specialties and polyols, thermoplastic polyurethanes, specialty films, and elastomers that are used in automotive and transportation, electrical, electronics and household appliances, construction, and healthcare industries, as well as composite resins for solar panel frames, laptops, floodlights, and electric vehicle batteries. The company markets its products through trading houses and distributors. It operates in Europe, the Middle East, Africa, Latin America, the United States, Canada, and the People's Republic of China. The company was founded in 1863 and is headquartered in Leverkusen, Germany.
Renault logo

Renault

OTCMKTS:RNLSY
Renault SA engages in the design, manufacture, sale, repair, maintenance, and leasing of motor vehicles in Europe, Eurasia, Africa, the Middle East, the Asia Pacific, and the Americas. It also engages in the design and production of parts and equipment used for manufacturing and operation vehicles. The company operates through Automotive, Sale Financing, and Mobility Services segments. Its Automotive segment produces, sells, and distributes passenger cars and light commercial vehicles; and invests in automotive-sector associates and joint ventures primarily in Nissan. The company's Sale Financing segment offers sale financing, leasing, maintenance, and services contract under the Mobilize Financial Services brand. Its Mobility Services segment provides mobility and energy solutions for electric vehicle users under the Mobilize brand. In addition, it is also involved in the design, manufacture, and sale of passenger cars and light commercial vehicles under the Renault, Dacia, Alpine, and Mobilize brands. Further, the company offers used vehicles and spare parts; and engages in business-to-business powertrain activities, and research and advanced engineering activities. Renault SA was founded in 1898 and is based in Boulogne-Billancourt, France.
SWEDISH ORPHAN/S logo

SWEDISH ORPHAN/S

OTCMKTS:SWTUY
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.